Leerink Partners Initiates Coverage On Obsidian Therapeutics with Outperform Rating, Announces Price Target of $32

Benzinga Newsdesk www.benzinga.com Positive 78.5%

Neg 0% Neu 0% Pos 78.5%

Leerink Partners initiates coverage on Obsidian Therapeutics (NASDAQ:OBX) with a Outperform rating and announces Price Target of $32.